Display options
Cite
van de Peppel IP, Rao A, Dommerholt MB, et al. The Beneficial Effects of Apical Sodium-Dependent Bile Acid Transporter Inactivation Depend on Dietary Fat Composition. Mol Nutr Food Res. 2020;e2000750doi: 10.1002/mnfr.202000750.
van de Peppel, I. P., Rao, A., Dommerholt, M. B., Bongiovanni, L., Thomas, R., de Bruin, A., Karpen, S. J., Dawson, P. A., Verkade, H. J., & Jonker, J. W. (2020). The Beneficial Effects of Apical Sodium-Dependent Bile Acid Transporter Inactivation Depend on Dietary Fat Composition. Molecular nutrition & food research, e2000750. https://doi.org/10.1002/mnfr.202000750
van de Peppel, Ivo P, et al. "The Beneficial Effects of Apical Sodium-Dependent Bile Acid Transporter Inactivation Depend on Dietary Fat Composition." Molecular nutrition & food research vol. (2020): e2000750. doi: https://doi.org/10.1002/mnfr.202000750
van de Peppel IP, Rao A, Dommerholt MB, Bongiovanni L, Thomas R, de Bruin A, Karpen SJ, Dawson PA, Verkade HJ, Jonker JW. The Beneficial Effects of Apical Sodium-Dependent Bile Acid Transporter Inactivation Depend on Dietary Fat Composition. Mol Nutr Food Res. 2020 Oct 20;e2000750. doi: 10.1002/mnfr.202000750. Epub 2020 Oct 20. PMID: 33079450; PMCID: PMC7757219.
Copy Download .nbib Format: NLM
Share it on

Mol Nutr Food Res. 2020 Oct 20;e2000750. doi: 10.1002/mnfr.202000750. Epub 2020 Oct 20.

The Beneficial Effects of Apical Sodium-Dependent Bile Acid Transporter Inactivation Depend on Dietary Fat Composition.

Molecular nutrition & food research

Ivo P van de Peppel, Anuradha Rao, Marleen B Dommerholt, Laura Bongiovanni, Rachel Thomas, Alain de Bruin, Saul J Karpen, Paul A Dawson, Henkjan J Verkade, Johan W Jonker

Affiliations

  1. Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.
  2. Department of Pediatrics, Emory University School of Medicine, 1760 Haygood Drive Northeast, Atlanta, GA 30322, USA.
  3. Dutch Molecular Pathology Centre, Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, Utrecht, 3584 CL, The Netherlands.

PMID: 33079450 PMCID: PMC7757219 DOI: 10.1002/mnfr.202000750

Abstract

SCOPE: The apical sodium-dependent bile acid transporter (ASBT, SLC10A2) is important in the enterohepatic cycling of bile acids and thereby in the intestinal absorption of lipids. ASBT inhibition has been shown to improve aspects of the metabolic syndrome, but the underlying mechanisms have remained unclear. Here, the effect of ASBT inhibition on the uptake of specific fatty acids and its consequences for diet-induced obesity and non-alcoholic fatty liver disease (NAFLD) are investigated.

METHODS: Intestinal fat absorption is determined in mice receiving an ASBT inhibitor and in Asbt

RESULTS: Both ASBT inhibition and Asbt gene inactivation reduce total fat absorption, particularly of SFAs. Asbt gene inactivation lowers bodyweight gain, improves insulin sensitivity, and decreases the NAFLD activity score upon feeding a HFD rich in SFAs, but not in PUFAs.

CONCLUSIONS: The beneficial metabolic effects of ASBT inactivation on diet-induced obesity depend on decreased intestinal absorption of SFAs, and thus on the dietary fatty acid composition. These findings highlight the importance of dietary fatty acid composition in the therapeutic effects of ASBT inhibition.

© 2020 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH GmbH.

Keywords: bile acid; enterohepatic circulation; fat absorption; obesity; steatosis

References

  1. Sci Transl Med. 2016 Sep 21;8(357):357ra122 - PubMed
  2. Front Biosci. 2001 Mar 01;6:D299-319 - PubMed
  3. Arch Intern Med. 1972 Oct;130(4):574-83 - PubMed
  4. J Lipid Res. 2008 Jul;49(7):1562-8 - PubMed
  5. Curr Protoc Mouse Biol. 2016 Dec 1;6(4):408-434 - PubMed
  6. Hepatology. 1996 Jul;24(1):241-7 - PubMed
  7. PLoS One. 2019 Jun 24;14(6):e0218459 - PubMed
  8. J Lipid Res. 2012 Dec;53(12):2791-6 - PubMed
  9. Am J Physiol. 1979 Jun;236(6):E721-7 - PubMed
  10. Am J Clin Nutr. 2000 Jul;72(1):174-80 - PubMed
  11. Nat Rev Gastroenterol Hepatol. 2014 Jan;11(1):55-67 - PubMed
  12. Can J Biochem Physiol. 1959 Aug;37(8):911-7 - PubMed
  13. Arch Biochem Biophys. 1971 Mar;143(1):22-36 - PubMed
  14. Mol Nutr Food Res. 2020 Oct 20;:e2000750 - PubMed
  15. Gastroenterology. 2017 May;152(7):1679-1694.e3 - PubMed
  16. Hepatology. 2005 Jun;41(6):1313-21 - PubMed
  17. Anal Biochem. 2004 Nov 1;334(1):117-26 - PubMed
  18. Hepatology. 2011 May;53(5):1784 - PubMed
  19. J Am Assoc Lab Anim Sci. 2011 Jul;50(4):488-94 - PubMed
  20. Am J Physiol Gastrointest Liver Physiol. 2020 Nov 1;319(5):G619-G625 - PubMed
  21. Gastroenterology. 2004 Jul;127(1):139-44 - PubMed
  22. Am J Physiol Gastrointest Liver Physiol. 2000 Dec;279(6):G1242-8 - PubMed
  23. Br J Nutr. 1976 Jan;35(1):77-87 - PubMed
  24. J Biol Chem. 1957 May;226(1):497-509 - PubMed
  25. J Lipid Res. 2019 Sep;60(9):1562-1572 - PubMed
  26. Nature. 1961 Jun 17;190:1106-7 - PubMed
  27. Am J Physiol Gastrointest Liver Physiol. 2020 Apr 1;318(4):G682-G693 - PubMed
  28. Nat Rev Endocrinol. 2014 Aug;10(8):488-98 - PubMed
  29. J Clin Invest. 1976 Jul;58(1):97-108 - PubMed
  30. J Basic Clin Pharm. 2016 Mar;7(2):27-31 - PubMed
  31. Front Med (Lausanne). 2020 Feb 25;7:60 - PubMed
  32. N Engl J Med. 2017 Jan 19;376(3):254-266 - PubMed
  33. J Lipid Res. 1989 May;30(5):719-30 - PubMed
  34. PLoS One. 2012;7(5):e37787 - PubMed
  35. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76 - PubMed
  36. Prog Lipid Res. 2009 Mar;48(2):101-15 - PubMed
  37. Atherosclerosis. 2013 Aug;229(2):374-80 - PubMed
  38. Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G494-502 - PubMed
  39. J Hepatol. 2015 Sep;63(3):697-704 - PubMed
  40. Am J Physiol Gastrointest Liver Physiol. 2013 Nov;305(9):G620-7 - PubMed
  41. J Hepatol. 2020 Aug;73(2):231-240 - PubMed
  42. J Biol Chem. 2003 Sep 5;278(36):33920-7 - PubMed
  43. J Lipid Res. 2007 Feb;48(2):278-87 - PubMed

Publication Types